Sarah J Ross (Sarah Ross)

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 4

Top Topics

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Molecular cancer therapeutics

Cancer research

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Jesse Boumelha, Sophie de Carné Trécesson, Emily K Law, Pablo Romero-Clavijo, Matthew A Coelho, Kevin W Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R Caswell, Miguel Murillo, David C Hancock, Prokopios P Argyris, William L Brown, Cameron Durfee, Lindsay K Larson, Rachel Isaksson Vogel, Alejandro Suarez-Bonnet, Simon Lawrence Priestnall, Philip East, Sarah J Ross, George Kassiotis, Miriam Molina-Arcas, Charles Swanton, Reuben Stewart Harris, Julian Downward
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations. Cancer research 82 (19) (2022)
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, Mustasin Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Federica Di Nicolantonio, Simon S McDade, Christopher J Scott, Shauna Lambe, Manisha Maurya, Andreas U Lindner, Jochen H M Prehn, Jose Sousa, Chris Winnington, Melissa J LaBonte, Sarah J Ross, Sandra Van Schaeybroeck
Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. Molecular cancer therapeutics (2022)
Atanu Chakraborty, Lyndsey Hanson, David Robinson, Hilary J Lewis, Sue Bickerton, Michael Davies, Radoslaw Polanski, Rebecca Whiteley, Alex Koers, James Atkinson, Tamara Baker, Ivan Del Barco Barrantes, Giovanni Ciotta, Jason G Kettle, Lukasz Magiera, Carla P Martins, Alison Peter, Eleanor M Wigmore, Zoe E Underwood, Sabina Cosulich, Michael Niedbala, Sarah J Ross
AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Molecular cancer therapeutics 21 (10) (2022)
Sarah J Ross, Alexey S Revenko, Lyndsey L Hanson, Rebecca Ellston, Anna Staniszewska, Nicky Whalley, Sanjay K Pandey, Mitchell Revill, Claire Rooney, Linda K Buckett, Stephanie K Klein, Kevin Hudson, Brett P Monia, Michael Zinda, David C Blakey, Paul D Lyne, A Robert Macleod
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Science translational medicine 9 (394) (2018)